Mezhlumyan Armen G, Tallerova Anna V, Povarnina Polina Y, Tarasiuk Aleksey V, Sazonova Nellya M, Gudasheva Tatiana A, Seredenin Sergey B
Department of Medicinal Chemistry, V.V. Zakusov Research Institute of Pharmacology, 125315 Moscow, Russia.
Department of Pharmacogenetics, V.V. Zakusov Research Institute of Pharmacology, 25315 Moscow, Russia.
Pharmaceuticals (Basel). 2022 Feb 24;15(3):284. doi: 10.3390/ph15030284.
Neurotrophins are considered as an attractive target for the development of antidepressants with a novel mechanism of action. Previously, the dimeric dipeptide mimetics of individual loops of nerve growth factor, NGF (GK-6, loop 1; GK-2, loop 4) and brain-derived neurotrophic factor, BDNF (GSB-214, loop 1; GTS-201, loop 2; GSB-106, loop 4) were designed and synthesized. All the mimetics of NGF and BDNF in vitro after a 5-180 min incubation in a HT-22 cell culture were able to phosphorylate the tropomyosin-related kinase A (TrkA) or B (TrkB) receptors, respectively, but had different post-receptor signaling patterns. In the present study, we conduct comparative research of the antidepressant-like activity of these mimetics at acute and subchronic administration in the forced swim test in mice. Only the dipeptide GSB-106 that in vitro activates mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK), phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) and phospholipase C-gamma (PLC) post-receptor pathways exhibited antidepressant-like activity (0.1 and 1.0 mg/kg, ip) at acute administration. At the same time, the inhibition of any one of these signaling pathways completely prevented the antidepressant-like effects of GSB-106 in the forced swim test. All the NGF mimetics were inactive after a single injection regardless of post-receptor in vitro signaling patterns. All the investigated dipeptides, except GTS-201, not activating PI3K/AKT in vitro unlike the other compounds, were active at subchronic administration. The data obtained demonstrate that the low-molecular weight BDNF mimetic GSB-106 that activates all three main post-receptor TrkB signaling pathways is the most promising for the development as an antidepressant.
神经营养因子被认为是开发具有新型作用机制的抗抑郁药的一个有吸引力的靶点。此前,已设计并合成了神经生长因子(NGF)各个环的二聚体二肽模拟物(GK-6,环1;GK-2,环4)以及脑源性神经营养因子(BDNF)的各个环的二聚体二肽模拟物(GSB-214,环1;GTS-201,环2;GSB-106,环4)。在HT-22细胞培养物中孵育5 - 180分钟后,所有NGF和BDNF的模拟物在体外分别能够使原肌球蛋白相关激酶A(TrkA)或B(TrkB)受体磷酸化,但具有不同的受体后信号传导模式。在本研究中,我们对这些模拟物在小鼠强迫游泳试验中急性和亚慢性给药时的抗抑郁样活性进行了比较研究。只有二肽GSB-106在体外激活有丝分裂原活化蛋白激酶/细胞外信号调节激酶(MAPK/ERK)、磷酸肌醇3-激酶/蛋白激酶B(PI3K/AKT)和磷脂酶C-γ(PLC)受体后途径,在急性给药时表现出抗抑郁样活性(0.1和1.0毫克/千克,腹腔注射)。同时,抑制这些信号通路中的任何一条都完全阻止了GSB-106在强迫游泳试验中的抗抑郁样作用。无论受体后体外信号传导模式如何,所有NGF模拟物单次注射后均无活性。除GTS-201外,所有研究的二肽在体外与其他化合物不同,不激活PI3K/AKT,但在亚慢性给药时具有活性。所获得的数据表明,激活所有三条主要的TrkB受体后信号通路的低分子量BDNF模拟物GSB-106作为抗抑郁药开发最有前景。